Gilead has agreed to donate HIV medication for up to 200,000 people each year for up to 11 years.
The big picture: Gilead's Truvada is used to reduce the risk of HIV infection, and is crucial to the Trump administration's goal to wipe out the disease by 2030.
Details: Truvada currently has a list price of more than $20,000 per year. If Gilead's second-generation HIV medication, Descovy, becomes available, the company will switch to donating that drug.
What they're saying: The AIDS Institute's Carl Schmid called the announcement a "very significant development" that "will free up the federal government from having to spend potentially billions of dollars" on the medication for the uninsured.
- Others were less positive. "The real cost of Truvada is about $60 a year. If you really wanted to cover everybody, you’d cut the price to everyone," Massachusetts General Hospital's Rochelle Walensky told the NYT. "If I put on my cynical hat, I think this is the way they make sure they grow the market for Descovy."
Go deeper: 2nd HIV patient achieves remission, signaling possible path to a cure
